Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $29,130.00 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $29.13, for a total value of $29,130.00. Following the completion of the transaction, the vice president now directly owns 34,258 shares in the company, valued at approximately $997,935.54. The trade was a 2.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Patrick Lamy also recently made the following trade(s):

• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.79, for a total transaction of $28,480.75.

Akero Therapeutics Price Performance

Shares of NASDAQ:AKRO opened at $28.71 on Thursday. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm has a 50-day simple moving average of $30.91 and a 200 day simple moving average of $27.36. Akero Therapeutics, Inc. has a fifty-two week low of $15.32 and a fifty-two week high of $37.00. The company has a market cap of $2.00 billion, a PE ratio of -7.66 and a beta of -0.23.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.96 EPS for the current year.

Wall Street Analysts Forecast Growth

AKRO has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research report on Monday, November 18th. Citigroup assumed coverage on Akero Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $65.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.83.

Hedge Funds Weigh In On Akero Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Exome Asset Management LLC bought a new position in Akero Therapeutics in the 3rd quarter valued at about $2,212,000. Barclays PLC lifted its stake in shares of Akero Therapeutics by 127.9% in the 3rd quarter. Barclays PLC now owns 127,668 shares of the company’s stock worth $3,662,000 after acquiring an additional 71,652 shares during the period. Y Intercept Hong Kong Ltd boosted its holdings in shares of Akero Therapeutics by 13.8% in the third quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock valued at $485,000 after acquiring an additional 2,049 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Akero Therapeutics during the third quarter valued at approximately $308,000. Finally, Wellington Management Group LLP raised its holdings in Akero Therapeutics by 54.4% during the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock worth $226,554,000 after purchasing an additional 2,782,029 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.